A Multimodal Risk Assessment and Prevention System for Adenovirus Pneumonia in Children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600117352

Enrollment

Unknown

Registered

2026-01-22

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenovirus pneumonia in children

Interventions

Group A:Methylprednisolone 2mg/kg/day

Group C:gamma globulin 1g/kg/day

Group B:Methylprednisolone 4mg/kg/day

Observation group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnostic criteria for adenovirus pneumonia: According to the pneumonia diagnostic standards in the 7th edition of Zhu Futang's Practical Pediatrics, the condition is characterized by respiratory manifestations including fever, cough, dyspnea, and pulmonary rales, accompanied by unilateral or bilateral abnormalities on chest imaging; adenovirus nucleic acid testing of nasopharyngeal aspirate must yield a positive result. 2.Criteria for diagnosing severe pneumonia in pediatric patients include the presence of any one of the following: Poor general condition; Refusal to eat or signs of dehydration; Altered mental status; Markedly increased respiratory rate (infants >70 breaths/min, older children >50 breaths/min); Cyanosis; Respiratory distress; Pulmonary infiltrates involving >=2/3 of the lung or multiple lobes; Pleural effusion; Pulse oximetry saturation =0.92; Extrapulmonary complications. 3.The patient and their legal guardian have signed the informed consent form for participation in this study.

Exclusion criteria

Exclusion criteria: 1.patients with primary or secondary immune deficiency/dysfunction, congenital heart disease, chronic liver or kidney disease, oncologic disorders, connective tissue disease, chronic lung disease; 2.Upon admission, pathogen testing revealed concurrent infections with other pathogens. 3.Parents/children of patients unwilling to participate; 4.The medical records are incomplete.

Design outcomes

Primary

Measure	Time frame
days of fever;adverse drug reaction;	—

Secondary

Measure	Time frame
Improvement in chest imaging;Improvement of inflammatory indicators;	—

Countries

China

Contacts

Public ContactYuanyuan Zhang

Children's Hospital,Zhejiang University School of Medicine

chzyy@zju.edu.cn+86 571 8173 2331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026